Serial No.: 10/661,804

IN THE CLAIMS:

Please amend the claims as follows:

1 – 11. (Cancelled).

12. (Currently Amended) A method to identify, monitor and/or remove CD4+ CD25+ regulatory T cells from human blood comprising the step of contacting the human blood with ligands specifically binding to the CD4 and CD25, and/or CTL-A4 entities on the T cells, whereby CD4+ CD25+ regulatory T cells present in human blood are identified, monitored, and/or removed from the human blood.

13 - 23. (Cancelled).

- 24. (Previously presented) The method of claim 12, wherein said ligands specifically binding to the CD4 and CD25 and/or CTL-A4 entities on the T cells are anti-CD4 antibodies and anti-CD25 antibodies and/or anti-CTL-A4 antibodies.
- 25. (Previously Presented) The method of claim 12, whereby CD4+ CD25+ T cells are removed from the human blood.
- 26. (Previously Presented) The method of claim 12, wherein said method further comprises utilizing immunoadsorption methods.
- 27. (Previously Presented) The method of claim 12, wherein said method further comprises utilizing a stimulating agent or antigen presenting cells.
- 28. (Previously Presented) The method of claim 12, wherein said method further comprises the step of testing the CD4+ CD25+ T cells for a regulatory property of CD4+ CD25+ T cells.

Serial No.: 10/661,804

- 29. (Previously Presented) The method of claim 28, wherein said step of testing the CD4+ CD25+ T cells comprises analyzing the CD4+ CD25+ T cells for a property selected from the group consisting of:
 - (a) constitutive expression of CTLA-4;
 - (b) being non-proliferative following stimulation via the T cell receptor;
 - (c) being in an anergic state;
 - (d) being in an anergic state that is partially reversed by IL-15;
 - (e) being in an anergic state that is partially reversed by IL-2 and IL-15;
 - (f) releasing IL-10 following stimulation with allogeneic mature dendritic cells;
- (g) releasing IL-10 following stimulation with anti-CD28 antibodies and immobilized anti-CD3 antibodies;
- (h) suppressing the activation and proliferation of CD4+ T cells in a coculture experiment;
- (i) suppressing the activation and proliferation of CD8+ T cells in a coculture experiment; and
 - (j) having a cytokine profile that differs from that of CD4+ CD25 T cells.
- 30. (Previously Presented) The method of claim 29, wherein said method comprises analyzing the CD4+ CD25+ T cells for the property of suppressing the activation and proliferation of CD4+ T cells in a coculture experiment, wherein said analyzing comprises determining whether said property of suppressing the activation and proliferation of CD4+ T cells is contact-dependent.
- 31. (Previously Presented) The method of claim 29, wherein said method comprises the step of analyzing the CD4+ CD25+ T cells for the property of suppressing the activation and proliferation of CD4+ T cells in a coculture experiment, wherein said analyzing comprises the use of CD4+ CD25+ T cells that have been activated and fixed.

Serial No.: 10/661,804

32. (Previously Presented) The method of claim 29, wherein said method comprises the step of analyzing the CD4+ CD25+ T cells for a cytokine profile of predominant secretion of IL-10 and only low levels of secretion of IL-2, IL-4, and IFN- γ .